NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free SGHT Stock Alerts $5.28 +0.10 (+1.93%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.14▼$5.4750-Day Range$4.02▼$5.8952-Week Range$1.04▼$11.20Volume61,089 shsAverage Volume221,867 shsMarket Capitalization$261.62 millionP/E RatioN/ADividend YieldN/APrice Target$4.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Sight Sciences alerts: Email Address Sight Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside12.9% Downside$4.60 Price TargetShort InterestBearish6.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$151,250 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.04) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.51 out of 5 starsMedical Sector911th out of 938 stocksSurgical & Medical Instruments Industry97th out of 97 stocks 1.0 Analyst's Opinion Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.60, Sight Sciences has a forecasted downside of 12.9% from its current price of $5.28.Amount of Analyst CoverageSight Sciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.22% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sight Sciences has recently increased by 17.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGHT. Previous Next 2.6 News and Social Media Coverage News SentimentSight Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sight Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for SGHT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Sight Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,250.00 in company stock.Percentage Held by Insiders27.10% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($1.04) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Sight Sciences Stock (NASDAQ:SGHT)Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Read More SGHT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGHT Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 26, 2024 | globenewswire.comSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare ConferenceMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 16, 2024 | finance.yahoo.comSGHT Apr 2024 5.000 callMarch 8, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Sight Sciences Inc Earnings CallMarch 7, 2024 | finance.yahoo.comSight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce ExpensesMarch 7, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 7, 2024 | benzinga.comSight Sciences: Q4 Earnings InsightsMarch 7, 2024 | msn.comSight Sciences GAAP EPS of -$0.22 beats by $0.12, revenue of $18.8M misses by $0.6MMarch 7, 2024 | globenewswire.comSight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial GuidanceMarch 6, 2024 | benzinga.comSight Sciences's Earnings: A PreviewFebruary 23, 2024 | finance.yahoo.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderFebruary 23, 2024 | finance.yahoo.comUVM Health Network and UnitedHealthcare reach last minute agreement on coverageFebruary 22, 2024 | globenewswire.comSight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024February 21, 2024 | finance.yahoo.comTen-Year Low Volatility Has Locals Piling Into Brazilian RealFebruary 21, 2024 | finance.yahoo.comSight Sciences (SGHT) to Expand in Europe With New LaunchFebruary 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Integer Holdings (ITGR) and Pacific Biosciences (PACB)February 15, 2024 | finanznachrichten.deSight Sciences, Inc.: Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | finance.yahoo.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | finance.yahoo.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 14, 2024 | globenewswire.comSight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter MeetingFebruary 3, 2024 | msn.comSight Sciences Executive Compensation Adjustments for 2024January 9, 2024 | finanznachrichten.deSight Sciences, Inc.: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial HighlightsJanuary 8, 2024 | finance.yahoo.comSight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial HighlightsDecember 29, 2023 | realmoney.thestreet.comPiper says Sight Sciences reimbursement update positive, still sees 'work to do'See More Headlines Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:SGHT CUSIPN/A CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees214Year FoundedN/APrice Target and Rating Average Stock Price Target$4.60 High Stock Price Target$5.50 Low Stock Price Target$4.00 Potential Upside/Downside-12.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,550,000.00 Net Margins-68.53% Pretax Margin-68.39% Return on Equity-41.94% Return on Assets-30.64% Debt Debt-to-Equity Ratio0.26 Current Ratio13.29 Quick Ratio12.65 Sales & Book Value Annual Sales$81.06 million Price / Sales3.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book2.14Miscellaneous Outstanding Shares49,550,000Free Float36,124,000Market Cap$261.62 million OptionableOptionable Beta2.76 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Paul Badawi (Age 49)Co-Founder, President, CEO & Director Comp: $920.3kDr. David Badawi M.D. (Age 54)Founder, CTO & Director Mr. Sam Boong Park (Age 63)Chief Operating Officer Comp: $531.78kMs. Alison Perry Bauerlein (Age 43)CFO & Treasurer Mr. Jeremy B. Hayden (Age 54)Chief Legal Officer Mr. Steve R. Tamayo Jr.VP and Chief Ethics & Compliance OfficerDr. Reay H. BrownChief Medical OfficerTom HuangHead of Corporate Strategy & DevelopmentMr. Matthew W. Link (Age 49)Chief Commercial Officer Mr. Stephen B. Thau J.D.SecretaryMore ExecutivesKey CompetitorsUtah Medical ProductsNASDAQ:UTMDTriSalus Life SciencesNASDAQ:TLSIAccurayNASDAQ:ARAYAngioDynamicsNASDAQ:ANGOInovio PharmaceuticalsNASDAQ:INOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 64,721 shares on 3/11/2024Ownership: 3.025%Barclays PLCBought 20,081 shares on 2/15/2024Ownership: 0.061%Wolverine Trading LLCBought 12,500 shares on 2/15/2024Ownership: 0.000%Prelude Capital Management LLCSold 6,200 shares on 2/15/2024Ownership: 0.021%Legal & General Group PlcSold 10,031 shares on 2/15/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions SGHT Stock Analysis - Frequently Asked Questions Should I buy or sell Sight Sciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sight Sciences in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGHT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGHT, but not buy additional shares or sell existing shares. View SGHT analyst ratings or view top-rated stocks. What is Sight Sciences' stock price target for 2024? 6 analysts have issued 1 year price targets for Sight Sciences' shares. Their SGHT share price targets range from $4.00 to $5.50. On average, they expect the company's stock price to reach $4.60 in the next twelve months. This suggests that the stock has a possible downside of 12.9%. View analysts price targets for SGHT or view top-rated stocks among Wall Street analysts. How have SGHT shares performed in 2024? Sight Sciences' stock was trading at $5.16 at the start of the year. Since then, SGHT stock has increased by 2.3% and is now trading at $5.28. View the best growth stocks for 2024 here. When is Sight Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our SGHT earnings forecast. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.13. The firm earned $18.75 million during the quarter, compared to the consensus estimate of $18.70 million. Sight Sciences had a negative net margin of 68.53% and a negative trailing twelve-month return on equity of 41.94%. During the same period last year, the business posted ($0.35) earnings per share. What guidance has Sight Sciences issued on next quarter's earnings? Sight Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $81.0 million-$85.0 million, compared to the consensus revenue estimate of $82.4 million. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share. Who are Sight Sciences' major shareholders? Sight Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (5.94%), Jackson Square Partners LLC (3.34%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Northern Trust Corp (0.41%) and Charles Schwab Investment Management Inc. (0.40%). Insiders that own company stock include D1 Capital Partners LP, David Badawi, Jeremy B Hayden, Jesse Selnick, Paul Badawi, Sam Boong Park and Staffan Encrantz. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGHT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.